NCT00004151 is a Phase 2 clinical trial of acridine carboxamide in Lung Cancer, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

Who is sponsoring NCT00004151?

NCT00004151 is sponsored by European Organisation for Research and Treatment of Cancer - EORTC.

What drugs are being tested in NCT00004151?

Interventions in NCT00004151: acridine carboxamide.

What condition does NCT00004151 study?

NCT00004151 studies Lung Cancer.

Is NCT00004151 still recruiting?

NCT00004151 is currently completed. Last updated 20 September 2012.

Last reviewed 2012-09-20 · How we verify

NCT00004151

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label Phase II Study on XR5000 Administered as a 5 Day Infusion in Advanced Non Small Cell Lung Cancer

Completed Phase 2 Last updated 20 September 2012

What this trial tests

Phase 2 trial testing acridine carboxamide in Lung Cancer in 15 participants. Completed.

Timeline

1 September 1999

Primary endpoint
1 November 2000

Quick facts

Lead sponsor	European Organisation for Research and Treatment of Cancer - EORTC
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Primary purpose	treatment
Enrollment	15
Start date	1 September 1999
Primary completion	1 November 2000
Sites	8 locations across Austria, Denmark, France, Germany, Italy, Spain

Drugs / interventions tested

acridine carboxamide — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

European Organisation for Research and Treatment of Cancer - EORTC — full company profile →

Who can join

18 and older, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of acridine carboxamide in treating patients who have advanced non-small cell lung cancer that cannot be treated with surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other European Organisation for Research and Treatment of Cancer - EORTC trials

Trials by the same sponsor.

NCT07425808 — FLT3-ITD Targeted Therapy in Fit AML Patients · Phase 2, PHASE3 · not yet recruiting
NCT06978062 — Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment · Phase 1 · not yet recruiting
NCT06809322 — Vorasidenib Maintenance for IDH Mutant Astrocytoma · Phase 3 · recruiting
NCT06990061 — Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, · NA · not yet recruiting
NCT06783348 — Radiopharmaceutical Treatment of Advanced Kidney Cancer · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00004151 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by European Organisation for Research and Treatment of Cancer - EORTC
Last refreshed: 20 September 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00004151.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing